Chunlan Pu
Impact in
-
- Peptidase Inhibition and Analysis
-
- Multiple Myeloma Research and Treatments
Papers in
- Oncology 11
- Peptidase Inhibition and Analysis 7
- PARP inhibition in cancer therapy 3
-
- Protein Degradation and Inhibitors 13
- Ubiquitin and proteasome pathways 9
- Histone Deacetylase Inhibitors Research 3
- Co-authors
- Rui Li (13 shared papers)Guoyi Yan (14 shared papers)Shirui Wang (10 shared papers)Xueyan Hou (9 shared papers)Xinyu Ma (9 shared papers)Suke Lan (8 shared papers)Hongjia Zhang (5 shared papers)Meng Zhou (6 shared papers)
- Journals
- European Journal of Medicinal Chemistry (10 papers)Journal of Medicinal Chemistry (3 papers)Bioorganic & Medicinal Chemistry (3 papers)MedChemComm (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)
- Partner nations
- ChinaNetherlandsGermany
In The Last Decade
Chunlan Pu
32 papers receiving 513 citations
Peers
Comparison fields: 5 of 61
- Oncology 145
- Hematology 60
- Molecular Biology 325
- Virology 11
- Pulmonary and Respiratory Medicine 63
Countries citing papers authored by Chunlan Pu
This map shows the geographic impact of Chunlan Pu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunlan Pu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunlan Pu more than expected).
Fields of papers citing papers by Chunlan Pu
This network shows the impact of papers produced by Chunlan Pu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunlan Pu. The network helps show where Chunlan Pu may publish in the future.
Co-authors
The 25 scholars most cited alongside Chunlan Pu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 59 | |
| 2 | 2021 | 43 | |
| 3 | 2022 | 39 | |
| 4 | 2017 | 39 | |
| 5 | 2023 | 32 | |
| 6 | 2016 | 32 | |
| 7 | 2023 | 25 | |
| 8 | 2024 | 24 | |
| 9 | 2009 | 23 | |
| 10 | 2022 | 20 | |
| 11 | 2022 | 19 | |
| 12 | 2024 | 19 | |
| 13 | 2022 | 18 | |
| 14 | 2021 | 15 | |
| 15 | 2019 | 14 | |
| 16 | 2024 | 13 | |
| 17 | 2017 | 13 | |
| 18 | 2024 | 11 | |
| 19 | 2021 | 9 | |
| 20 | 2024 | 9 |
About Chunlan Pu
Chunlan Pu is a scholar working on Oncology, Molecular Biology, Virology, Hepatology and Infectious Diseases, having authored 33 papers that have together received 522 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (9 papers), Peptidase Inhibition and Analysis (7 papers), HIV/AIDS drug development and treatment (3 papers), HIV Research and Treatment (3 papers), PARP inhibition in cancer therapy (3 papers), Histone Deacetylase Inhibitors Research (3 papers) and Computational Drug Discovery Methods (2 papers). The work is most often cited by research in Oncology (145 citations), Hematology (60 citations), Molecular Biology (325 citations), Virology (11 citations) and Pulmonary and Respiratory Medicine (63 citations). Chunlan Pu has collaborated with scholars based in China, Netherlands and Germany. Frequent co-authors include Rui Li, Guoyi Yan, Shirui Wang, Xueyan Hou, Xinyu Ma, Suke Lan, Hongjia Zhang, Meng Zhou, Jianyou Shi and Dan Luo. Their work appears in journals such as European Journal of Medicinal Chemistry, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, MedChemComm and Bioorganic & Medicinal Chemistry Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.